Drugs that contain Trametinib Dimethyl Sulfoxide
1. Mekinist patents expiration
MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7378423 | NOVARTIS | Pyrimidine compound and medical use thereof |
May, 2027
(3 years from now) | |
| US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 6 months from now) | |
|
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
|
US7378423 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(3 years from now) | |
| US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(7 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(7 years from now) | |
| US8580304 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9271941 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9155706 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
| US9399021 | NOVARTIS | Pharmaceutical composition |
Jan, 2032
(8 years from now) | |
|
US9155706 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US8580304 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9271941 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
|
US9399021 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(8 years from now) | |
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
| New Indication (I) | Jun 22, 2025 |
| Pediatric Exclusivity (PED) | Dec 22, 2025 |
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...
Dosage: TABLET;ORAL
More Information on Dosage
MEKINIST family patents
